Ukr.Biochem.J. 2019; Volume 91, Issue 2, Mar-Apr, pp. 52-62


Blood coagulation parameters in rats with acute radiation syndrome receiving activated carbon as a preventive remedy

V. Chernyshenko1, E. Snezhkova2, M. Mazur2, T. Chernyshenko1,
T. Platonova1, O. Sydorenko2, E. Lugovskoy1, V. Nikolaev2

1Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
2RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv

Received: 13 December 2018; Accepted: 20 March 2019

Radiation-induced coagulopathy (RIC) is one of the major causes of death during acute radiation syndrome (ARS). The aim of this study was to characterize the responses of the hemostasis system to ARS of a moderate level on the 1st and 9th days after irradiation. We aimed to identify molecular markers of the blood coagulation system that are most affected by ARS and to estimate the enterosorption effect on the development of irradiation-induced changes. Platelet aggregation rate, activated partial thromboplastin time (APTT) and fibrinogen concentration were determined by standard methods. Level of protein C (PC) was measured using­ chromogenic substrate S2366 (p-Glu-Pro-Arg-pNa) and Agkistrodon halys halys snake venom activa­ting enzyme. Functionally inactive forms of prothrombin (FIFPs) were determined using two activators in parallel – thromboplastin or prothrombin activator from Echis multisqumatis venom. Rats of both irradia­ted groups had a higher risk of intravascular clotting in comparison to both control groups. Statistically significant shortening of clotting time in the APTT test (24 ± 4 s vs. 33 ± 5 s) and increased fibrinogen concentration (4.2 ± 0.6 mg/ml vs. 3.2 ± 0.3 mg/ml) were detected. Both parameters were normalized on the 9th day after irradiation. However the platelet count was decreased (0.3∙106 ± 0.05∙106 1/μl vs. 0.145∙106 ± 0.04∙106 1/μl) due to the impaired megakaryocytic function. The level of PC was decreased after X-ray irradiation (70 ± 10%) and partly restored on the 9th day after irradiation (87 ± 10%). Administration of activated carbon (AC) inhibited the drop in the PC concentration after X-ray irradiation (86 ± 15%) and accelerated its restoration on the 9th day (103 ± 14%). The statistically significant accumulation of FIFPs was detected in blood plasma of irradia­ted rats at the 1st and 9th days after irradiation. No FIFPs were found in any irradiated rat treated with AC. Characterization of the hemostasis system of rats that were exposed to a semilethal dose of X-rays allowed us to select parameters that can be used for monitoring of ARS development. Apart of from basic coagulation tests (APTT) and the measurement of platelet aggregation, fibrinogen and protein C level we can recommend the determination of FIFPs as a useful tool for estimation of the hemostasis response after irradiation with X-rays. This test indicates the intravascular thrombin generation and can help predict thrombotic complication or disseminated intravascular coagulation. Determination of FIFPs in blood plasma of irradia­ted rats allowed us to study the enterosorption effect on the development of irradiation-induced changes. It was shown that enterosorption with AC prevented accumulation of FIFPs which appears to be a newly discovered anti-thrombotic effect of therapy with AC. ARS influenced hemostasis by inducing thrombin generation (indicated by FIFPs generation), low-grade inflammation (indicated by PC concentration decrease) and thrombocytopenia. Enterosorption with AC minimizes inflammation and pro-coagulant processes caused by a moderate dose of X-ray irradiation. Accumulation of FIFPs can be assumed to be one of the most sensitive markers of the blood coagulation response to X-ray irradiation.

Keywords: , , , ,


  1. Macià I Garau M, Lucas Calduch A, López EC. Radiobiology of the acute radiation syndrome. Rep Pract Oncol Radiother. 2011 Jul 6;16(4):123-30. PubMed, PubMedCentral, CrossRef
  2. Denham JW, Hauer-Jensen M, Peters LJ.  Is it time for a new formalism to categorize normal tissue radiation injury? Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1105-6. PubMed, CrossRef
  3. Gourmelon P, Benderitter M, Bertho JM, Huet C, Gorin NC, De Revel P. European consensus on the medical management of acute radiation syndrome and analysis of the radiation accidents in Belgium and Senegal. Health Phys. 2010 Jun;98(6):825-32. PubMed, CrossRef
  4. Krigsfeld GS, Savage AR, Billings PC, Lin L, Kennedy AR. Evidence for radiation-induced disseminated intravascular coagulation as a major cause of radiation-induced death in ferrets. Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):940-6.  PubMed, PubMedCentral, CrossRef
  5. Kennedy AR, Maity A, Sanzari JK. A Review of Radiation-Induced Coagulopathy and New Findings to Support Potential Prevention Strategies and Treatments. Radiat Res. 2016 Aug;186(2):121-40. PubMed, PubMedCentral, CrossRef
  6. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018 Feb 22;131(8):845-854. PubMed, CrossRef
  7. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010 Feb;38(2 Suppl):S26-34. PubMed, CrossRef
  8. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005 Nov;131(4):417-30. PubMed, CrossRef
  9. Schaue D, Micewicz ED, Ratikan JA, Xie MW, Cheng G, McBride WH. Radiation and inflammation. Semin Radiat Oncol. 2015 Jan;25(1):4-10. PubMed, PubMed, CrossRef
  10. Hryschenko VA, Tomchuk VA, Lytvynenko OM, Chernyshenko VO, Gryschuk VI, Platonova TM. An estimate of protein synthesis in liver under induced hepatitis. Ukr Biokhim Zhurn.  2011 Jan-Feb;83(1):63-8. (In Ukrainian). PubMed
  11. Dziuba OS, Chernyshenko VO, Hudz IeA, Kasatkina LO, Chernyshenko TM, Klymenko PP, Kosiakova HV, Platonova TM, Hula NM, Lugovskoy EV. Blood coagulation and aortic wall integrity in rats with obesity-induced insulin resistance. Ukr Biochem J. 2018; 90(2): 14-23.  CrossRef
  12. Shevchuk OO, Snezhkova EA, Bardakhivskaya KI, Nikolaev VG. Adsorptive treatment of acute radiation sickness: past achievements and new prospects. Hemoperfusion, Plasmaperfusion And Other Clinical Uses Of General, Biospecific, Immuno And Leucocyte Adsorbents. 2017;Chapter 8:245-256.  CrossRef
  13. Sarnatskaya VV, Sakhno L, Paziuk LM, Yushko LA, Rodionova NK, Maslenniy VN, Sidorenko AS, Nikolaev V. Highly activated carbon enterosorbent mediates the suppression of paraneoplastic syndrome associated with Lewis lung carcinoma in mice. Exp Oncol. 2018 Mar;40(1):33-41. PubMed, CrossRef
  14. Solovjov DA, Platonova TN, Ugarova TP. Purification and characterization of ecamulin – a new prothrombin activator from the Echis multisquamatus snake venom. Biochemistry (Mosc). 1996;61(6):785-793.
  15. Gornitskaia OV, Platonova TN. Isolation and properties of the protein C activator from Agkistrodon halys halys venom. Biomed Khim. 2003 Sep-Oct;49(5):470-8. (In Russian). PubMed
  16. Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, Lussana F, Pugliano MT, Michelson AD. Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost. 2013; 11(6): 1183-1189. PubMed, CrossRef
  17. Korolova DS, Chernyshenko TM, Gornytska OV, Chernyshenko VO, Platonova TN. Meizothrombin preparation and its role in fibrin formation and platelet aggregation. Adv Biosci Biotechnol. 2014;5(7):588-595.  CrossRef
  18. Korolova DS, Chernyshenko VO, Platonova TN, Chernyshenko TM, Lugovskoy EV. Detection of Prethrombin 1 in Human Blood Plasma. Int Blood Res Rev. 2016;5(2):1-7. CrossRef
  19. Gershkovich AA, Kibirev VK. Chromogenic and fluorogenic peptide substrates of proteolytic enzymes. Bioorg Khim. 1988 Nov;14(11):1461-88. (In Russian). PubMed
  20. Capoor MN, Stonemetz JL, Baird JC, Ahmed FS, Awan A, Birkenmaier C, Inchiosa MA Jr, Magid SK, McGoldrick K, Molmenti E, Naqvi S, Parker SD, Pothula SM, Shander A, Steen RG, Urban MK, Wall J, Fischetti VA. Prothrombin Time and Activated Partial Thromboplastin Time Testing: A Comparative Effectiveness Study in a Million-Patient Sample. PLoS One. 2015 Aug 11;10(8):e0133317. PubMed, PubMedCentral, CrossRef
  21. Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ. Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis. 2010 Jul;21(5):459-63. PubMed, CrossRef
  22. Abdullah WZ. Shortened activated partial thromboplastin time (APTT): a simple but important marker of hypercoagulable state during acute coronary event. Coronary Artery Disease – New Insights and Novel Approaches. InTech, 2012. 157-166 pp.  CrossRef
  23. Zhang X, Bai B. Correlation of fibrinogen level and absorbance change in both PT and APTT clotting curves on BCSXP. J Nanjing Med Univ. 2008;22(3):193-198. CrossRef
  24. Jain S, Gautam V, Naseem S. Acute-phase proteins: As diagnostic tool. J Pharm Bioallied Sci. 2011 Jan;3(1):118-27. PubMed, PubMedCentral, CrossRef
  25. Bouwens EA, Stavenuiter F, Mosnier LO.  Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost. 2013 Jun;11(Suppl 1):242-53. PubMed, PubMedCentral, CrossRef
  26. Dainiak N. Hematologic consequences of exposure to ionizing radiation. Exp Hematol. 2002 Jun;30(6):513-28. PubMed, CrossRef
  27. Chen S, Su Y, Wang J. ROS-mediated platelet generation: a microenvironment-dependent manner for megakaryocyte proliferation, differentiation, and maturation. Cell Death Dis. 2013 Jul 11;4(7):e722. PubMed, PubMedCentral, CrossRef
  28. Wazny LD, Ariano RE. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy. 2000 Mar;20(3):292-307. PubMed, CrossRef
  29. Venkatesulu BP, Mahadevan LS, Aliru ML, Yang X, Bodd MH, Singh PK, Yusuf SW, Abe JI, Krishnan S. Radiation-Induced Endothelial Vascular Injury: A Review of Possible Mechanisms. JACC Basic Transl Sci. 2018 Aug 28;3(4):563-572. PubMed, PubMedCentral, CrossRef
  30. van Hinsbergh VW. Endothelium—role in regulation of coagulation and inflammation. Semin Immunopathol. 2012 Jan;34(1):93-106. PubMed, PubMedCentral, CrossRef
  31. Coenen DM, Mastenbroek TG, Cosemans JMEM. Platelet interaction with activated endothelium: mechanistic insights from microfluidics. Blood. 2017 Dec 28;130(26):2819-2828. PubMed, CrossRef
  32. ten Cate H. Tissue factor-driven thrombin generation and inflammation in atherosclerosis. Thromb Res. 2012 May;129(Suppl 2):S38-40.  PubMed, CrossRef
  33. Popović M, Smiljanić K, Dobutović B, Syrovets T, Simmet T, Isenović ER. Thrombin and vascular inflammation. Mol Cell Biochem. 2012 Jan;359(1-2):301-13. PubMed, CrossRef
  34. Krishnaswamy S. The transition of prothrombin to thrombin. J Thromb Haemost. 2013 Jun;11(Suppl 1):265-76. PubMed, PubMedCentral, CrossRef
  35. Chen Z, Pelc LA, Di Cera E. Crystal structure of prethrombin-1. Proc Natl Acad Sci USA. 2010 Nov 9;107(45):19278-83.  PubMed, PubMedCentral, CrossRef
  36. McDuffie FC, Giffin C, Niedringhaus R, Mann KG, Owen CA Jr, Bowie EJ, Peterson J, Clark G, Hunder GG. Prothrombin, thrombin and prothrombin fragments in plasma of normal individuals and of patients with laboratory evidence of disseminated intravascular coagulation. Thromb Res. 1979;16(5-6):759-73. PubMed, CrossRef
  37. Suttie JW. Vitamin K in Health and Disease. Boca Raton: CRC Press, 2009. 231 p.  CrossRef
  38. Bovill EG, Soll RF, Lynch M, Bhushan F, Landesman M, Freije M, Church W, McAuliffe T, Davidson K, Sadowski J. Vitamin K1 metabolism and the production of des-carboxy prothrombin and protein C in the term and premature neonate.  Blood. 1993 Jan 1;81(1):77-83. PubMed

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.